Altus Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Altus Pharmaceuticals
Starting stock price: $19.19
Ending stock price: $5.18
Percent Change: -73.01%

Details: In July Altus lost orphan drug status for its experimental pancreatic insufficiency therapy; the FDA said the number of patients with the condition exceeds the 200,000 mark required for an orphan drug. But the real blow came in December when Genentech return the North American rights to ALTU-238, a growth hormone. Altus is looking for another partner for the drug.

More News:
Altus shares dive as Genentech hands back drug rights. Report
Altus loses orphan drug status. Report
Altus inks $140M pact for human growth hormone. Report
Altus stock plunges on clinical trial delay. Report

Altus Pharmaceuticals - Worst Pharma Stocks of 2007

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.